Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Apr 30

PMID 33919121

Citations 35

Authors

Claire Dunois

Affiliations

Soon will be listed here.

Abstract

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous anticoagulant therapies. DOACs directly, selectively, and reversibly inhibit factors IIa or Xa. The coagulation effect follows the plasma concentration-time profile of the respective anticoagulant. The short half-life of a DOAC constrains the daily oral intake. Because DOACs have predictable pharmacokinetic and pharmacodynamic responses at a fixed dose, they do not require monitoring. However in specific clinical situations and for particular patient populations, testing may be helpful for patient management. The effect of DOACs on the screening coagulation assays such as prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) is directly linked to reagent composition, and clotting time can be different from reagent to reagent, depending on the DOAC's reagent sensitivity. Liquid chromatography-mass spectrometry (LC-MS/MS) is considered the gold standard method for DOAC measurement, but it is time consuming and requires expensive equipment. The general consensus for the assessment of a DOAC is clotting or chromogenic assays using specific standard calibrators and controls. This review provides a short summary of DOAC properties and an update on laboratory methods for measuring DOACs.

Citing Articles

Validation of a whole blood coagulometer sensitive to the direct oral anticoagulants.

Bakhru S, Jiang X, Chen L, Osmani D, Kronen K, Mootoo D Sci Rep. 2025; 15(1):7355.

PMID: 40025084 PMC: 11873143. DOI: 10.1038/s41598-025-92201-7.

Direct oral anticoagulant use in oral surgery: insights from a systematic review.

Yefet E, Givol N, Pesis M Oral Maxillofac Surg. 2025; 29(1):51.

PMID: 39907806 DOI: 10.1007/s10006-025-01348-0.

Predictors of Venous Thromboembolism Following Geriatric Distal Femur Fracture Fixation: Are These Patients at Higher Risk Compared With Hip Fracture Patients?.

Seddio A, Vasudevan R, Gouzoulis M, Jabbouri S, Grauer J, Fram B J Am Acad Orthop Surg Glob Res Rev. 2025; 9(1).

PMID: 39823200 PMC: 11745856. DOI: 10.5435/JAAOSGlobal-D-24-00246.

Development of Machine-learning Model to Predict Anticoagulant Use and Type in Geriatric Traumatic Brain Injury Using Coagulation Parameters.

Fujiwara G, Okada Y, Suehiro E, Yatsushige H, Hirota S, Hasegawa S Neurol Med Chir (Tokyo). 2024; 65(2):61-70.

PMID: 39721668 PMC: 11891141. DOI: 10.2176/jns-nmc.2024-0066.

Assessing the Predictive Value of the SAMe-TT2R2 Score for Poor Anticoagulation Control in a Diverse Ethnic Population.

Mohamed S, Nik Abdul Rahman N, Tan J, Selvam T, Zulkifly H Hosp Pharm. 2024; :00185787241300293.

PMID: 39619886 PMC: 11607723. DOI: 10.1177/00185787241300293.

References

Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M . Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010; 50(7):743-53. DOI: 10.1177/0091270009351883. View

Gibson C, Halaby R, Korjian S, Daaboul Y, Arbetter D, Yee M . The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017; 185:93-100. DOI: 10.1016/j.ahj.2016.12.004. View

Connolly S, Eikelboom J, Dorian P, Hohnloser S, Gretler D, Sinha U . Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013; 34(20):1498-505. PMC: 3659305. DOI: 10.1093/eurheartj/eht039. View

Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S . Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs. 2013; 13(5):331-42. PMC: 3781304. DOI: 10.1007/s40256-013-0029-0. View

Gosselin R, Adcock D, Bates S, Douxfils J, Favaloro E, Gouin-Thibault I . International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost. 2018; 118(3):437-450. DOI: 10.1055/s-0038-1627480. View

Wienen W, Stassen J, Priepke H, Ries U, Hauel N . In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98(1):155-62. View

Coons J, Albert L, Bejjani A, Iasella C . Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism. Pharmacotherapy. 2020; 40(3):204-210. DOI: 10.1002/phar.2369. View

He K, Luettgen J, Zhang D, He B, Grace Jr J, Xin B . Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011; 36(3):129-39. DOI: 10.1007/s13318-011-0037-x. View

Spyropoulos A, Al-Badri A, Sherwood M, Douketis J . Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost. 2016; 14(5):875-85. DOI: 10.1111/jth.13305. View

10.

Kitchen S, Gray E, Mackie I, Baglin T, Makris M . Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014; 166(6):830-41. DOI: 10.1111/bjh.12975. View

11.

Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K . In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3(3):514-21. DOI: 10.1111/j.1538-7836.2005.01166.x. View

12.

Patel J, Chitongo P, Czuprynska J, Roberts L, Patel R, Arya R . Normal prothrombin times in the presence of therapeutic levels of apixaban--in-vivo experience from King's College Hospital. Br J Haematol. 2014; 169(1):152-3. DOI: 10.1111/bjh.13187. View

13.

Takatsuki S, Kimura T, Sugimoto K, Misaki S, Nakajima K, Kashimura S . Real-world monitoring of direct oral anticoagulants in clinic and hospitalization settings. SAGE Open Med. 2017; 5:2050312117734773. PMC: 5648091. DOI: 10.1177/2050312117734773. View

14.

Schmohl M, Gansser D, Moschetti V, Stangier J . Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis. Thromb Res. 2015; 135(3):532-6. DOI: 10.1016/j.thromres.2014.12.021. View

15.

Ruff C, Giugliano R, Braunwald E, Morrow D, Murphy S, Kuder J . Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385(9984):2288-95. DOI: 10.1016/S0140-6736(14)61943-7. View

16.

Vakkalagadda B, Frost C, Byon W, Boyd R, Wang J, Zhang D . Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016; 16(2):119-27. DOI: 10.1007/s40256-015-0157-9. View

17.

Mueck W, Borris L, Dahl O, Haas S, Huisman M, Kakkar A . Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008; 100(3):453-61. View

18.

Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M . Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015; 13(11):2012-20. DOI: 10.1111/jth.13139. View

19.

Skeppholm M, Hjemdahl P, Antovic J, Muhrbeck J, Eintrei J, Ronquist-Nii Y . On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. Thromb Res. 2014; 134(4):783-9. DOI: 10.1016/j.thromres.2014.06.016. View

20.

Lange U, Nowak G, Bucha E . Ecarin chromogenic assay--a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2004; 33(4):184-91. DOI: 10.1159/000081506. View